Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 750 of 2026 entries
View as:

An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01070927 Org: User:
Start: 01/31/10 End: 08/31/10 Due: 08/31/11

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

Phase: N/A Priority: Normal
NCT ID: NCT01493271 Org: User:
Start: 12/31/11 End: 11/30/12 Due: 11/30/13

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Phase: N/A Priority: Normal
NCT ID: NCT02431208 Org: User:
Start: 07/22/15 End: 03/19/21 Due: 03/19/22

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06883240 Org: User:
Start: 04/29/25 End: 11/01/26 Due: 11/01/27

Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT00876538 Org: User:
Start: 03/31/09 End: 09/30/10 Due: 09/30/11

A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

Phase: N/A Priority: Normal
NCT ID: NCT04487067 Org: User:
Start: 08/25/20 End: 08/13/24 Due: 08/13/25

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

Phase: N/A Priority: Normal
NCT ID: NCT01798576 Org: User:
Start: 11/30/12 End: 06/30/15 Due: 06/30/16

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05232825 Org: User:
Start: 05/03/22 End: 06/06/25 Due: 06/06/26

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01194570 Org: User:
Start: 03/02/11 End: 12/31/22 Due: 12/31/23

An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01712347 Org: User:
Start: 10/11/12 End: 07/01/16 Due: 07/01/17

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00045032 Org: User:
Start: 11/30/01 End: 06/30/15 Due: 06/30/16

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Phase: N/A Priority: Normal
NCT ID: NCT02657434 Org: User:
Start: 04/30/16 End: 12/13/22 Due: 12/13/23

SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.

Phase: N/A Priority: Normal
NCT ID: NCT00545480 Org: User:
Start: 07/31/06 End: 03/31/09 Due: 03/31/10

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00825149 Org: User:
Start: 02/28/09 End: 11/30/15 Due: 11/30/16

A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT00642967 Org: User:
Start: 06/30/08 End: 08/31/10 Due: 08/31/11

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01194414 Org: User:
Start: 09/30/10 End: 08/31/13 Due: 08/31/14

A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT00493155 Org: User:
Start: 10/31/05 End: 02/28/09 Due: 02/28/10

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS

Phase: N/A Priority: Normal
NCT ID: NCT00002257 Org: User:
Start: - End: - Due: -

ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01041404 Org: User:
Start: 09/30/05 End: 06/30/10 Due: 06/30/11

Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids

Phase: N/A Priority: Normal
NCT ID: NCT00048009 Org: User:
Start: 10/25/02 End: 02/02/04 Due: 02/02/05

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

Phase: N/A Priority: Normal
NCT ID: NCT00642460 Org: User:
Start: 05/31/08 End: 08/31/14 Due: 08/31/15

A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

Phase: N/A Priority: Normal
NCT ID: NCT04374253 Org: User:
Start: 01/26/21 End: 03/06/23 Due: 03/06/24

H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01991340 Org: User:
Start: 11/30/08 End: 02/28/13 Due: 02/28/14

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06862869 Org: User:
Start: 03/26/25 End: 03/30/29 Due: 03/30/30

A Study of Vemurafenib in Participants With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01307397 Org: User:
Start: 03/01/11 End: 02/24/16 Due: 02/24/17